

-- 26. A method according to claim 12, whereby predominant interaction at peripheral receptors is achieved by administering the mGluR antagonist in such a way that it does not substantially penetrate the CNS. --

-- 27. A composition according to claim 11, whereby predominant interaction at peripheral receptors is achieved by administering the mGluR antagonist transdermally. --

A3 -- 28. A method according to claim 12, whereby predominant interaction at peripheral receptors is achieved by administering the mGluR antagonist transdermally. --

-- 29. A composition according to claim 11, whereby the condition to be treated is inflammatory or neuropathic pain. --

-- 30. A method according to claim 12, whereby the condition to be treated is inflammatory or neuropathic pain. --

REMARKS

By the foregoing amendment to the specification, a cross-reference has been inserted beneath the title on page 1.


Claims 13-18 have been amended to eliminate their multiple dependencies. In this connection, attached hereto is an Appendix which represents a marked-up version of the changes made to Claims 13-18 by the foregoing amendments.

New Claims 19-30 are directed to certain of the subject matter excised from Claims 13-18.

Early and favorable consideration of the claims is respectfully awaited.

Respectfully submitted,

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027


Joseph J. Broyan
Agent for Applicants
Reg. No. 28,631
(908) 522-6921

Date: March 29, 2001

Encl.: Appendix (marked-up version of the changes made)

APPENDIX

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 13-18 have been amended as follows:

13. (amended) A use, ~~composition or method~~ according to ~~anyone of~~ claims 9 ~~to 12~~, whereby the mGluR antagonist is a specific mGluR5 antagonist.

14. (amended). A use, ~~composition or method~~ according to ~~anyone of~~ claims 9 ~~to 12~~, whereby predominant interaction at peripheral receptors is achieved by using a mGluR antagonist, which does not substantially penetrate the CNS.

15. (amended) A use, ~~composition or method~~ according to ~~anyone of~~ claims 9 ~~to 12~~, whereby predominant interaction at peripheral receptors is achieved by using a mGluR antagonist which does not substantially cross the blood-brain barrier.

16. (amended) A use, ~~composition or method~~ according to ~~anyone of~~ claims 9 ~~to 12~~, whereby predominant interaction at peripheral receptors is achieved by administering the mGluR antagonist in such a way that it does not substantially penetrate the CNS.

17. (amended) A use, ~~composition or method~~ according to ~~anyone of~~ claims 9 ~~to 12~~, whereby predominant interaction at peripheral receptors is achieved by administering the mGluR antagonist transdermally.

18. (amended) A use, ~~composition or method~~ according to ~~anyone of~~ claims 9 ~~to 17~~, whereby the condition to be treated is inflammatory or neuropathic pain.